tiprankstipranks
Verici Dx Foresees TutiviaTM Revenue Shift to FY25
Company Announcements

Verici Dx Foresees TutiviaTM Revenue Shift to FY25

Verici Dx Plc (GB:VRCI) has released an update.

Don't Miss Our Christmas Offers:

Verici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, has announced a delay in revenue recognition for its TutiviaTM test to FY25 due to a postponed Medicare coverage determination. Despite the delay, the company maintains a strong cash position and expects year-end balances to meet market expectations, with continued collaborations and anticipated revenue acceleration once insurance coverage is established in 2025.

For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskVerici Dx Launches Groundbreaking Transplant Risk Assay
TipRanks UK Auto-Generated NewsdeskVerici Dx Plc Reports Revenue Growth and Strategic Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App